MicroRNA profiles help assess cancer risk in Lynch syndrome carriers

In his doctoral dissertation completed at the University of Jyväskylä, Finland, Tero Sievänen demonstrates that the cancer risk of Lynch syndrome carriers can be assessed based on circulating microRNA profiles.

Merck winds down Phase 3 TIGIT/PD-1 combo study due to safety-related dropouts

A large number of patient dropouts caused by immune side effects have forced Merck to end a late-stage trial of its anti-TIGIT drug vibostolimab in

May 14, 2024

Lobe Sciences Announces Frederick D. Sancilio Ph.D. to Join Board of Directors | Psychedelic Invest

Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) (“Lobe” or the “Company”), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced

May 31, 2024

Ahead of Novo’s CagriSema readout, Lilly returns to a promising new class of obesity drugs

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.